GlassScriptPhysician profile
Joju Thomas Variath
NPI 1871541490
$3,154.41
in general payments reported to CMS, 2019-2025
16 companies · $479 in 2025
The $479 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94.04 · 2020: $262 · 2021: $372 · 2022: $687 · 2023: $882 · 2024: $378 · 2025: $479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,738.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,738.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $566.14 | 2020-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Ironshore Pharmaceuticals INC. | $450.39 | 2019-2024 | Jornay Pm |
| Abbvie INC. | $428.07 | 2022-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $320.81 | 2021-2023 | Caplyta |
| Vanda Pharmaceuticals INC. | $251.36 | 2024-2025 | Fanapt, Hetlioz |
| Supernus Pharmaceuticals, INC. | $192.14 | 2021-2025 | Qelbree |
| Neurocrine Biosciences, INC. | $158.40 | 2020-2024 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $121.89 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $118.77 | 2021-2023 | Austedo Xr |
| Corium, LLC | $114.70 | 2022-2023 | Azstarys |
| Indivior INC. | $111.36 | 2022-2023 | Perseris |
| Lundbeck LLC | $92.59 | 2020-2022 | |
| Alkermes, INC. | $82.44 | 2022-2023 | Aristada, Lybalvi, Vivitrol |
| Collegium Pharmaceutical, INC. | $76.59 | 2025 | Jornay Pm |
| Axsome Therapeutics, INC. | $39.87 | 2023-2025 | Auvelity |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $28.89 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joju Variath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.